Summary

Modern drug discovery increasingly depends on biochemical assays that deliver fast, reliable, and reproducible insights across diverse enzyme classes. Yet for many teams—whether in pharma, biotech, or contract research—assay development remains one of the most time-consuming steps in launching a new drug discovery program. Researchers often struggle with sourcing enzymes, validating reaction conditions, optimizing buffers, and selecting the correct detection format.

To solve these challenges, BellBrook Labs created Enzolution™ Assay Systems—ready-to-use enzyme + assay solutions that provide a streamlined, modular, and highly reproducible starting point for enzymatic screening and inhibitor discovery. Each Enzolution system includes a well-characterized enzyme, an optimized reaction buffer, essential cofactors, and a matched detection assay from BellBrook’s industry-leading Transcreener® product family.

The result is a unified platform that dramatically accelerates hit identification, IC₅₀ determination, and mechanism-of-action studies across ATPases, helicases (ATPase mode), sirtuins, PARPs, PARG, CD38, exonucleases, and other important drug-target classes.

This article provides a comprehensive introduction to the Enzolution platform, its benefits, its integration with Transcreener assays, and real-world use cases across emerging therapeutic areas. At the end, you’ll find a complete mapping of each Enzolution enzyme system to its correct detection assay—your definitive guide to selecting the right kit for your research program.

What Are Enzolution Assay Systems?

Enzolution assay systems are turnkey biochemical assay kits built to eliminate the friction and uncertainty of early assay development. Each system includes:

• A validated recombinant enzyme
• An optimized reaction buffer and cofactors
• A matching Transcreener or specialty BellBrook assay
• A detailed protocol with recommended starting conditions
• Suggested enzyme and substrate concentrations
• Benchmark Z′-factor data
• Guidance for screening, hit triage, and IC₅₀ generation

Rather than sourcing enzymes from multiple vendors, building assay conditions from scratch, or troubleshooting detection chemistry, researchers receive a fully integrated system designed for immediate screening.

Enzolution systems are currently available for:

• CD38
• DDX1
• DDX3
• DDX5
• DDX17
• DDX41
• DHX9
• MDA5
• RIG-I
• POLQ
• PARG
• PARP1
• PARP2
• SIRT1
• SIRT2
• SIRT3
• TREX1
• WRN

This portfolio covers many of today’s most relevant therapeutic areas, including innate immunity, oncology, synthetic lethality, DNA damage response, neuroinflammation, epigenetics, and metabolic regulation.

Why Enzolution Accelerates Modern Drug Discovery

Drug discovery programs are under pressure to evaluate more targets, generate better data, and move faster into hit-to-lead phases. Enzolution was designed to meet these needs.

1. It Dramatically Accelerates Assay Development

Traditional assay development can require:

• protein production
• purification
• activity screening
• buffer optimization
• substrate titration
• validating signal linearity
• assessing DMSO tolerance
• troubleshooting detection chemistry

This process can take weeks to months.

Enzolution replaces that entire workflow with:

• pre-validated enzymatic conditions
• recommended ATP, NAD⁺, ADPR, or DNA substrate levels
• known Km ranges (when applicable)
• verified Z′ > 0.7 starting points
• validated DMSO tolerance
• matched detection chemistry optimized for each enzyme

Most teams can begin pilot screening within 48–72 hours of receiving the kit.

2. It Frees Up Internal Resources

Internal assay development consumes both time and staff bandwidth. This includes molecular biologists, protein expression teams, enzymologists, and assay development specialists.

With Enzolution:

• no internal protein expression is needed
• no detection assay optimization required
• no troubleshooting kinase-vs-ATPase-vs-NADase-vs-PARP chemistry
• standardized workflow lowers overall resource requirements

CROs especially benefit because Enzolution reduces variability between client projects, allowing them to scale operations more efficiently.

3. It Ensures Consistency Across Diverse Enzymes

One of the most overlooked bottlenecks in assay development is assay fragmentation. Running dozens of enzymatic assays with different detection formats (ELISA, luminescence, coupled optical assays, gel-based assays, etc.) dramatically complicates data analysis and reproducibility.

Enzolution systems integrate directly with Transcreener assays, known for:

• direct detection
• no coupling enzymes
• mix-and-read simplicity
• compatibility with 96-, 384-, and 1536-well formats
• excellent Z′ values for HTS
• low false-positive rates

This consistency creates a unified platform across enzyme families—even when mechanisms differ.

4. It Supports Challenging and Emerging Drug Targets

Many modern drug targets are hard to assay due to:

• nucleic acid dependence (RIG-I, MDA5, DDX family)
• multi-domain structure
• conformational complexity (POLQ, WRN)
• requirement for long-substrate DNA or RNA
• instability during purification
• sensitivity to buffer composition

BellBrook’s team develops each Enzolution kit using assay conditions optimized specifically for that enzyme’s biochemistry. This drastically reduces the risk of failed screens, flat activity curves, or non-reproducible results.

5. It Reduces False Positives and Improves Hit Quality

Because Transcreener assays measure reaction products (ADP, AMP, OAADPr, ADPR, pADPr), they avoid problems typical of other assay formats, such as:

• redox cycling
• off-pathway substrate conversion
• reagent interference
• false signal amplification

Enzolution systems paired with Transcreener provide:

• higher data integrity
• better hit confirmation
• consistent IC₅₀ values
• easier SAR decision-making

This makes them ideal for both hit-finding and lead-optimization workflows.

How Enzolution Systems Integrate with Transcreener Assays

A major benefit of the Enzolution platform is its modularity. BellBrook’s detection chemistries—ADP², OAADPr, pADPr, ADPR, and the DAMP Exonuclease Assay—cover a wide array of enzymatic mechanisms.

Below are the major detection technologies involved.

Transcreener ADP² Assay (ATPase, Helicase ATPase Mode)

Used with:

• ATP-dependent helicases (DDX family, DHX9)
• innate immune ATPases (RIG-I, MDA5)
• DNA repair ATPases (WRN)
• synthetic lethality targets (POLQ ATPase domain)

ADP² measures ADP directly, with no coupling steps, making it the ideal platform for low-turnover or difficult ATPases.

Transcreener OAADPr SIRT Assay (SIRT1, SIRT2, SIRT3)

Sirtuins convert NAD⁺ → OAADPr, not ADP, so they require a specialized detection format. BellBrook’s OAADPr assay directly measures this product using a homogeneous fluorescence-based readout.

This is the only commercially available direct, mix-and-read OAADPr assay suitable for HTS.

Transcreener pADPr PARP Assay (PARP1, PARP2)

PARP1 and PARP2 produce poly-ADP-ribose (PAR) chains, while PARG releases mono- and oligo-ADP-ribose fragments by removing PAR. The Transcreener pADPr assay enables direct, antibody-based detection of these products.

This provides a robust and quantitative readout suitable for:

• PARG inhibitor identification
• PARylation mechanism studies

Transcreener ADPR Assay (CD38, PARG)

CD38 cleaves NAD⁺ to produce ADPR, requiring a unique fluorescent detection system optimized to measure this product directly.

This assay is ideal for:

• CD38 inhibitor discovery
• PARP inhibitor screening
• metabolic and immune modulation studies
• cellular signaling research

dAMP Exonuclease Assay (TREX1)

TREX1 is a DNA exonuclease involved in autoimmune disease, cancer, and innate immunity. Unlike ATPases or NADases, it requires an optical detection format that monitors cleavage of oligonucleotide substrates.

BellBrook’s dAMP Exonuclease Assay provides a direct, homogeneous measurement of TREX1 activity without gel-based methods.

Practical Advantages in HTS and Lead Optimization

Once a target enters screening, Enzolution systems provide multiple advantages across the discovery funnel.

1. Faster Pilot Screens

Teams can immediately:

• Validate activity
• Confirm signal linearity
• Establish assay windows
• Run mini-pilot plates
• Begin hit triage

This accelerates go/no-go decisions.

2. Easy Scaling to 1536-Well Formats

Because Transcreener assays are homogeneous and highly sensitive, scaling is straightforward. Many groups run:

• 384-well HTS
• 1536-well ultra-HTS
• automated dose-response curves

without needing to modify the detection chemistry.

3. Cleaner IC₅₀ Curves

Direct detection simplifies curve fitting and reduces ambiguous readouts caused by coupling failure or off-target reactions.

Enzolution systems support:

• standard IC₅₀ curves
• Ki determinations
• enzyme titrations
• mechanistic evaluation (competitive vs. uncompetitive, etc.)

4. Improved Hit Quality and Lower Attrition

Because BellBrook’s detection platforms avoid signal interference and artificial amplification, many customers report lower false-positive hit rates.

This improves downstream efficiency by reducing the burden of:

• counter-screens
• orthogonal assays
• retest validation
• medicinal chemistry follow-ups

Use Cases Across Enzyme Families

To highlight the practical impact of Enzolution kits, here are representative use cases across major target categories.

ATP-Dependent Helicases and ATPases (DDX, DHX9, WRN, POLQ, RIG-I, MDA5)

Applications:

• innate immune modulation
• antiviral screening
• cancer drug discovery
• synthetic lethality exploitation
• nucleic acid metabolism research

Enzolution systems provide:

• validated ATPase activity
• optimized buffer conditions
• streamlined inhibitor profiling

Sirtuins (SIRT1, SIRT2, SIRT3)

Applications:

• aging and metabolism research
• neuroinflammation
• cancer biology
• metabolic disease

The direct detection of OAADPr allows researchers to avoid slow, multi-step sirtuin assays that rely on coupled enzymes or labeled peptides.

PARP1, PARP2

Applications:

• DDR inhibitor discovery
• PAR dynamics studies
• synthetic lethality approaches
• oncology therapeutics

Transcreener’s pADPr system excels in both high-turnover and more challenging low-PAR environments.

CD38, PARG

Applications:

• immunology
• NAD⁺ signaling
• inflammation
• metabolic regulation

ADPR detection provides a clean and quantitative method for CD38 and PARG inhibitor screening.

TREX1

Applications:

• autoimmune disease mechanisms
• innate immunity
• DNA damage and repair
• inflammatory signaling

The dAMP Exonuclease Assay offers a breakthrough: a no-gel, homogeneous format for monitoring exonuclease activity.

Enzolution → Detection Assay Mapping